Overview

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Status:
Completed
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Avelumab
Capecitabine
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin